1. Home
  2. Team
  3. Conrad Crans

Conrad joined MVM in 2024. Prior to MVM, he worked at ClearView Healthcare Partners where he supported life science companies on strategy and commercialization across therapeutic areas, including oncology and immunology, and diligenced numerous therapeutic modalities for private equity firms. He received a B.A. summa cum lade in Biology with a minor in Financial Economics from Dartmouth College.

Latest news

Hologic agrees to acquire Gynesonics
October 14, 2024
Quell Therapeutics Expands Manufacturing Capabilities Through Partnership with eXmoor Pharma
September 24, 2024
Stryker agrees to acquire Vertos Medical
August 22, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
August 20, 2024
Providence Medical Technology, Inc. Announces FDA Clearance of CORUS™ Navigation Access System for Use with Medtronic’s StealthStation™ Surgical Navigation in Posterior Spinal Fusion
June 13, 2024
Nalu PNS System achieves significant and durable pain reduction, meeting the primary endpoint of the COMFORT RCT study
June 4, 2024
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
April 15, 2024
Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
GT Medical Technologies Names Per Langoe As CEO
February 20, 2024
MVM invests in icotec
January 24, 2024
View all